GlassScriptPhysician profile
Christina Raynor
NPI 1659086387
$5,996.20
in general payments reported to CMS, 2019-2025
25 companies · $2,713 in 2025
The $2,713 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $795 · 2024: $2,489 · 2025: $2,713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,745 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,745.21 |
| Education | $250.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,403.62 | 2023-2025 | |
| Janssen Biotech, INC. | $819.45 | 2023-2025 | Tremfya |
| Galderma Laboratories, L.P. | $471.01 | 2025 | Nemluvio, Aklief |
| Ucb, INC. | $458.37 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $455.44 | 2023-2025 | Winlevi, Absorica Ld |
| Amgen INC. | $434.24 | 2023-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $353.02 | 2024-2025 | |
| Dermavant Sciences, INC. | $283.65 | 2023-2024 | Vtama |
| Genzyme Corporation | $155.78 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $151.99 | 2023-2024 | |
| Lilly USA, LLC | $137.23 | 2023-2025 | Olumiant, Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $134.92 | 2024-2025 | Libtayo |
| Pfizer INC. | $113.56 | 2023-2025 | |
| Organon LLC | $98.85 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $79.55 | 2024-2025 | Sotyktu |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $74.60 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $68.77 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $59.22 | 2025 | Cabtreo, Jublia, Siliq |
| Incyte Corporation | $57.08 | 2023-2025 | Opzelura |
| Biofrontera INC. | $56.75 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.22 | 2024 | Spevigo |
| Journey Medical Corporation | $29.63 | 2025 | |
| Leo Pharma INC. | $24.01 | 2025 | Adbry |
| W. L. Gore & Associates, INC. | $16.35 | 2023 | Gore Synecor Biomaterial |
| Verrica Pharmaceuticals INC. | $13.89 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Raynor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.